Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein-bound uremic toxins (PBUTs) are a broad class of small, low molecular weight toxic molecules that accumulate in the bloodstream of patients with impaired kidney function, especially chronic kidney disease. These toxins are generated mainly by gut microbial metabolism of dietary proteins and are characterized by a strong binding affinity to plasma proteins, primarily albumin, which makes them difficult to eliminate by standard dialysis methods. PBUT accumulation is implicated in the development of uremic syndrome, cardiovascular disease, inflammation, and immune dysfunction. Key representatives of this group include indoxyl sulfate, p-cresyl sulfate, hippuric acid, among others. Due to their problematic removal and central role in disease pathology, PBUTs are the focus of ongoing research and therapeutic innovation, particularly around displacing them from albumin to enhance their clearance[1][3][4][6][7].
Competitive displacement from albumin binding sites to increase the free fraction and facilitate removal by dialysis or filtration
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein-bound uremic toxin (PBUT).